期刊
JOURNAL OF HEPATOLOGY
卷 52, 期 4, 页码 514-522出版社
ELSEVIER
DOI: 10.1016/j.jhep.2010.01.014
关键词
Hepatitis B virus; HBsAg; Chronic hepatitis B; HBV-genotype; HBV-DNA
资金
- BMBF [IFB-Tx 37]
- Deutsche Forschungsgemeinschaft
Background & Aims: The quantifiable level of HBsAg has been suggested as a predictor of treatment response in chronic hepatitis B. However, there is limited information on HBsAg levels considering the dynamic natural course of HBV-infection. This study aimed to determine HBsAg levels in the different phases of HBV-infection in European HBsAg-positive patients. Methods: 226 HBV-monoinfected patients, not undergoing antiviral therapy, were analyzed in a cross-sectional study. Patients were categorized according to the phase of HBV-infection: HBeAg(+) immune tolerance phase (IT, n = 30), immune clearance phase (IC, n = 48), HBeAg(-) low-replicative phase (LR, n = 68), HBeAg(-) hepatitis (ENH, n = 68), and acute hepatitis B (n = 12). HBsAg was quantified and correlated with HBV-DNA, HBV-genotypes and clinical parameters. In addition, 30 LR-patients were followed longitudinally. Results: HBsAg levels were higher in IT-patients and IC-patients compared to LR-patients and ENH-patients (4.96/4.37/3.09/3.87-log(10) IU/ml, p < 0.001). HBsAg showed a strong correlation with HBV-DNA during acute hepatitis B (R = 0.79, p < 0.01). Correlation of HBsAg and HBV-DNA was weak or missing when analyzing different phases of persistent HBV-infection separately. However, associations between HBsAg and HBV-DNA were observed in patients infected with HBV-genotype D but not with HBV-genotype A. LR-patients with HBV-reactivation during follow-up (increase of HBV-DNA > 2000 IU/ml) showed > 3-fold higher baseline HBsAg levels with a NPV of 95% for an HBsAg cut-off of 3500 IU/ml. Conclusions: HBsAg levels show significant differences during the natural course of HBV-infection and between HBV-genotypes. These findings may have important implications for understanding the natural history of HBV-infection and for using quantitative HBsAg as a diagnostic tool, i.e. as a marker for predicting HBV-reactivation. (c) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据